Please use this identifier to cite or link to this item: https://ahro.austin.org.au/austinjspui/handle/1/26091
Title: Efficacy and Safety of Parenteral High-Dose Vitamin C Therapy in Pediatric Patients: A Scoping Review.
Austin Authors: Yanase, Fumitaka ;Raman, Sainath;Naorungroj, Thummaporn ;McCarthy, Avril;Cree, Michele;Schlapbach, Luregn J;Bellomo, Rinaldo 
Affiliation: Department of Pharmacy, Queensland Children's Hospital, South Brisbane, QLD, Australia
Pediatric Intensive Care Unit, Queensland Children's Hospital, South Brisbane, QLD, Australia
Department of Intensive Care, Siriraj Hospital, Mahidol University, Bangkok, Thailand. 6 Department of Anaesthesia, Northern Health, Epping, VIC, Australia
Intensive Care
Australian and New Zealand Intensive Care Research Centre, Monash University, Melbourne, VIC, Australia
Child Health Research Centre, The University of Queensland, Brisbane, QLD, Australia
Department of Intensive Care Medicine and Neonatology, and Children's Research Center, University Children's Hospital Zurich, University of Zurich, Zurich, Switzerland
Department of Medicine and Radiology, Centre for Integrated Critical Care, University of Melbourne, Melbourne, VIC, Australia
Issue Date: Jun-2021
Date: 2021-02-26
Publication information: Pediatric Critical Care Medicine 2021; 22(6): 561-571
Abstract: Recently, several adult trials have investigated the potential benefit of high-dose vitamin C therapy in critically ill patients. In pediatric patients, little is known on the efficacy, safety, and risk of high-dose vitamin C therapy. We aimed to review the efficacy and potential harm associated with high-dose vitamin C treatment. We searched MEDLINE, EMBASE, Cochrane Library, and National Institute of Health Clinical Trials Register. We included studies in neonatal and pediatric patients who received IV or intra-arterial high-dose vitamin C (ascorbic acid) defined as greater than or equal to 75 mg/kg/d. Two independent investigators screened articles and extracted data. We found 1,364 articles, assessed 193 full texts for eligibility, and identified 12 eligible studies. These studies included 855 patients, with 194 receiving high-dose vitamin C. The age of patients who received high-dose vitamin C ranged from 2 hours after delivery to 8.4 years (median 2.4 yr), and the vitamin C dose ranged from 100 to 1,500 mg/kg/d (median 260.5 mg/kg/d). Four studies were double-blind randomized controlled trials, and no clinical efficacy outcome was reported in favor of or against vitamin C. Furthermore, no adverse event or signal of harm was reported with high-dose vitamin C. In 12 studies with 194 children treated with parenteral high-dose vitamin C, there was no evidence of clinical efficacy or inferior clinical outcomes in double-blind randomized controlled trials, and no reported harmful effects. These findings justify further investigations of this treatment in children.
URI: https://ahro.austin.org.au/austinjspui/handle/1/26091
DOI: 10.1097/PCC.0000000000002686
Journal: Pediatric Critical Care Medicine
PubMed URL: 33729732
ISSN: 1529-7535
Type: Journal Article
Appears in Collections:Journal articles

Show full item record

Page view(s)

60
checked on Dec 3, 2024

Google ScholarTM

Check


Items in AHRO are protected by copyright, with all rights reserved, unless otherwise indicated.